| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 983 | 2008 |
| The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects D Voora, SH Shah, I Spasojevic, S Ali, CR Reed, BA Salisbury, ... Journal of the American college of cardiology 54 (17), 1609-1616, 2009 | 535 | 2009 |
| The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and SimvastatinInduced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014 | 456 | 2014 |
| The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and SimvastatinInduced Myopathy RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ... Clinical Pharmacology & Therapeutics 92 (1), 112-117, 2012 | 360 | 2012 |
| Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention LH Cavallari, CR Lee, AL Beitelshees, RM Cooper-DeHoff, JD Duarte, ... JACC: Cardiovascular Interventions 11 (2), 181-191, 2018 | 263 | 2018 |
| Phenotype standardization for statininduced myotoxicity A Alfirevic, D Neely, J Armitage, H Chinoy, RG Cooper, R Laaksonen, ... Clinical Pharmacology & Therapeutics 96 (4), 470-476, 2014 | 243 | 2014 |
| Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype D Voora, C Eby, MW Linder, PE Milligan, BL Bukaveckas, HL McLeod, ... Thrombosis and haemostasis 93 (04), 700-705, 2005 | 243 | 2005 |
| Genetic-based dosing in orthopedic patients beginning warfarin therapy EA Millican, PA Lenzini, PE Milligan, L Grosso, C Eby, E Deych, G Grice, ... Blood, The Journal of the American Society of Hematology 110 (5), 1511-1515, 2007 | 222 | 2007 |
| The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and StatinAssociated Musculoskeletal … RM CooperDeHoff, M Niemi, LB Ramsey, JA Luzum, EK Tarkiainen, ... Clinical Pharmacology & Therapeutics 111 (5), 1007-1021, 2022 | 147 | 2022 |
| Effect of genetic variations on ticagrelor plasma levels and clinical outcomes C Varenhorst, N Eriksson, A Johansson, BJ Barratt, E Hagström, ... European heart journal 36 (29), 1901-1912, 2015 | 139 | 2015 |
| A host-based RT-PCR gene expression signature to identify acute respiratory viral infection AK Zaas, T Burke, M Chen, M McClain, B Nicholson, T Veldman, EL Tsalik, ... Science translational medicine 5 (203), 203ra126-203ra126, 2013 | 138 | 2013 |
| A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans D Voora, DC Koboldt, CR King, PA Lenzini, CS Eby, R PorcheSorbet, ... Clinical Pharmacology & Therapeutics 87 (4), 445-451, 2010 | 125 | 2010 |
| The pharmacogenetics of coumarin therapy D Voora, HL McLeod, C Eby, BF Gage Future Medicine Ltd 6 (5), 503-513, 2005 | 124 | 2005 |
| Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response D Voora, SH Shah, CR Reed, J Zhai, DR Crosslin, C Messer, ... Circulation: Cardiovascular Genetics 1 (2), 100-106, 2008 | 107 | 2008 |
| Clinical application of cardiovascular pharmacogenetics D Voora, GS Ginsburg Journal of the American College of Cardiology 60 (1), 9-20, 2012 | 101 | 2012 |
| The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a realworld setting LH Cavallari, AL Beitelshees, KV Blake, LG Dressler, JD Duarte, A Elsey, ... Clinical and translational science 10 (3), 143, 2017 | 88 | 2017 |
| Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheterdirected atrial fibrillation ablation TW Wallace, BD Atwater, JP Daubert, D Voora, AL Crowley, TD Bahnson, ... Journal of cardiovascular electrophysiology 21 (8), 849-852, 2010 | 83 | 2010 |
| Platelets amplify endotheliopathy in COVID-19 TJ Barrett, MI Cornwell, K Myndzar, CC Rolling, Y Xia, K Drenkova, ... Science Advances 7 (37), eabh2434, 2021 | 81 | 2021 |
| Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events D Voora, D Cyr, J Lucas, JT Chi, J Dungan, TA McCaffrey, R Katz, ... Journal of the American College of Cardiology 62 (14), 1267-1276, 2013 | 81 | 2013 |
| Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics AL Beitelshees, D Voora, JP Lewis Pharmacogenomics and Personalized Medicine, 43-61, 2015 | 77 | 2015 |
Geoffrey S GinsburgCMSO, All of Us Research Program @ National Institutes of Health; Adjunct Professor @ Duke U在 duke.edu 的电子邮件经过验证
